These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36330334)

  • 1. Increased osteoclastogenesis contributes to bone loss in the Costello syndrome
    Nandi S; Chennappan S; Andrasch Y; Fidan M; Engler M; Ahmad M; Tuckermann JP; Zenker M; Cirstea IC
    Front Cell Dev Biol; 2022; 10():1000575. PubMed ID: 36330334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms underlying cognitive deficits in a mouse model for Costello Syndrome are distinct from other RASopathy mouse models.
    Schreiber J; Grimbergen LA; Overwater I; Vaart TV; Stedehouder J; Schuhmacher AJ; Guerra C; Kushner SA; Jaarsma D; Elgersma Y
    Sci Rep; 2017 Apr; 7(1):1256. PubMed ID: 28455524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An attenuated phenotype of Costello syndrome in three unrelated individuals with a HRAS c.179G>A (p.Gly60Asp) mutation correlates with uncommon functional consequences.
    Gripp KW; Sol-Church K; Smpokou P; Graham GE; Stevenson DA; Hanson H; Viskochil DH; Baker LC; Russo B; Gardner N; Stabley DL; Kolbe V; Rosenberger G
    Am J Med Genet A; 2015 Sep; 167A(9):2085-97. PubMed ID: 25914166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetic mechanisms of mutation-dependent Harvey Ras activation and their relevance for the development of Costello syndrome.
    Wey M; Lee J; Jeong SS; Kim J; Heo J
    Biochemistry; 2013 Nov; 52(47):8465-79. PubMed ID: 24224811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HRAS germline mutations impair LKB1/AMPK signaling and mitochondrial homeostasis in Costello syndrome models.
    Dard L; Hubert C; Esteves P; Blanchard W; Bou About G; Baldasseroni L; Dumon E; Angelini C; Delourme M; Guyonnet-Dupérat V; Claverol S; Fontenille L; Kissa K; Séguéla PE; Thambo JB; Nicolas L; Herault Y; Bellance N; Dias Amoedo N; Magdinier F; Sorg T; Lacombe D; Rossignol R
    J Clin Invest; 2022 Apr; 132(8):. PubMed ID: 35230976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duplication of Glu37 in the switch I region of HRAS impairs effector/GAP binding and underlies Costello syndrome by promoting enhanced growth factor-dependent MAPK and AKT activation.
    Gremer L; De Luca A; Merbitz-Zahradnik T; Dallapiccola B; Morlot S; Tartaglia M; Kutsche K; Ahmadian MR; Rosenberger G
    Hum Mol Genet; 2010 Mar; 19(5):790-802. PubMed ID: 19995790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome.
    Rosenberger G; Meien S; Kutsche K
    Hum Mutat; 2009 Mar; 30(3):352-62. PubMed ID: 19035362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations.
    Gripp KW; Lin AE
    Genet Med; 2012 Mar; 14(3):285-92. PubMed ID: 22261753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased bone mineral density in Costello syndrome.
    Leoni C; Stevenson DA; Martini L; De Sanctis R; Mascolo G; Pantaleoni F; De Santis S; La Torraca I; Persichilli S; Caradonna P; Tartaglia M; Zampino G
    Mol Genet Metab; 2014 Jan; 111(1):41-5. PubMed ID: 24246682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paternal uniparental disomy 11p15.5 in the pancreatic nodule of an infant with Costello syndrome: Shared mechanism for hyperinsulinemic hypoglycemia in neonates with Costello and Beckwith-Wiedemann syndrome and somatic loss of heterozygosity in Costello syndrome driving clonal expansion.
    Gripp KW; Robbins KM; Sheffield BS; Lee AF; Patel MS; Yip S; Doyle D; Stabley D; Sol-Church K
    Am J Med Genet A; 2016 Mar; 170(3):559-64. PubMed ID: 26572961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C4ST-1/CHST11-controlled chondroitin sulfation interferes with oncogenic HRAS signaling in Costello syndrome.
    Klüppel M; Samavarchi-Tehrani P; Liu K; Wrana JL; Hinek A
    Eur J Hum Genet; 2012 Aug; 20(8):870-7. PubMed ID: 22317973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuated phenotype of Costello syndrome and early death in a patient with an HRAS mutation (c.179G>T; p.Gly60Val) affecting signalling dynamics.
    Gripp KW; Kolbe V; Brandenstein LI; Rosenberger G
    Clin Genet; 2017 Sep; 92(3):332-337. PubMed ID: 28139825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studying Metabolic Abnormalities in the Costello Syndrome HRAS G12V Mouse Model: Isolation of Mouse Embryonic Fibroblasts and Their In Vitro Adipocyte Differentiation.
    Fidan M; Chennappan S; Cirstea IC
    Methods Mol Biol; 2021; 2262():397-409. PubMed ID: 33977491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome.
    Niihori T; Aoki Y; Okamoto N; Kurosawa K; Ohashi H; Mizuno S; Kawame H; Inazawa J; Ohura T; Arai H; Nabatame S; Kikuchi K; Kuroki Y; Miura M; Tanaka T; Ohtake A; Omori I; Ihara K; Mabe H; Watanabe K; Niijima S; Okano E; Numabe H; Matsubara Y
    J Hum Genet; 2011 Oct; 56(10):707-15. PubMed ID: 21850009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional analysis of a duplication (p.E63_D69dup) in the switch II region of HRAS: new aspects of the molecular pathogenesis underlying Costello syndrome.
    Lorenz S; Lissewski C; Simsek-Kiper PO; Alanay Y; Boduroglu K; Zenker M; Rosenberger G
    Hum Mol Genet; 2013 Apr; 22(8):1643-53. PubMed ID: 23335589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mice with an Oncogenic HRAS Mutation are Resistant to High-Fat Diet-Induced Obesity and Exhibit Impaired Hepatic Energy Homeostasis.
    Oba D; Inoue SI; Miyagawa-Tomita S; Nakashima Y; Niihori T; Yamaguchi S; Matsubara Y; Aoki Y
    EBioMedicine; 2018 Jan; 27():138-150. PubMed ID: 29254681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy.
    Estep AL; Tidyman WE; Teitell MA; Cotter PD; Rauen KA
    Am J Med Genet A; 2006 Jan; 140(1):8-16. PubMed ID: 16372351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEK-inhibitor-mediated rescue of skeletal myopathy caused by activating Hras mutation in a Costello syndrome mouse model.
    Tidyman WE; Goodwin AF; Maeda Y; Klein OD; Rauen KA
    Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 34553752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndrome.
    Gripp KW; Lin AE; Nicholson L; Allen W; Cramer A; Jones KL; Kutz W; Peck D; Rebolledo MA; Wheeler PG; Wilson W; Al-Rahawan MM; Stabley DL; Sol-Church K
    Am J Med Genet A; 2007 Jul; 143A(13):1472-80. PubMed ID: 17551924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contributions of intrinsic mutation rate and selfish selection to levels of de novo HRAS mutations in the paternal germline.
    Giannoulatou E; McVean G; Taylor IB; McGowan SJ; Maher GJ; Iqbal Z; Pfeifer SP; Turner I; Burkitt Wright EM; Shorto J; Itani A; Turner K; Gregory L; Buck D; Rajpert-De Meyts E; Looijenga LH; Kerr B; Wilkie AO; Goriely A
    Proc Natl Acad Sci U S A; 2013 Dec; 110(50):20152-7. PubMed ID: 24259709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.